Novartis AG ADR (NVS)vsSutro Biopharma (STRO)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $280.79B
STRO
Sutro Biopharma
$35.39
+2.02%
HEALTHCARE · Cap: $556.51M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 55200% more annual revenue ($56.67B vs $102.48M). NVS leads profitability with a 24.7% profit margin vs -186.5%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
STRO
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.2%
Fair Value
$109.78
Current Price
$147.85
$38.07 premium
Margin of Safety
+74.0%
Fair Value
$60.45
Current Price
$35.39
$25.06 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 1.6B in free cash flow
No standout strengths identified
Areas to Watch
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -1810.0% — below average capital efficiency
Revenue declined 21.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bull Case : STRO
STRO has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Bear Case : STRO
The primary concerns for STRO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while STRO is a turnaround play — different risk/reward profiles.
STRO carries more volatility with a beta of 1.31 — expect wider price swings.
NVS is growing revenue faster at 2.2% — sustainability is the question.
NVS generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 23/100), backed by strong 24.7% margins. STRO offers better value entry with a 74.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Sutro Biopharma
HEALTHCARE · BIOTECHNOLOGY · USA
Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?